{
  "relationships": [
    {
      "entity1": "Almorexant",
      "entity2": "Orexin",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "Almorexant is now mainly used as a commercial specific inhibitor of the orexin system in animal studies due to safety issues."
    },
    {
      "entity1": "Filorexant",
      "entity2": "Insomnia",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "Although filorexant has also shown a certain sleep-promoting effect, there are few clinical or experimental studies on sleep-related aspects of filorexant in recent years."
    },
    {
      "entity1": "Seltorexant",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        6
      ],
      "evidence_text": "As for selective ORAs, orexin receptor 2 antagonist seltorexant still has not yet reached phase 3."
    },
    {
      "entity1": "Suvorexant",
      "entity2": "Insomnia",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia."
    },
    {
      "entity1": "Lemborexant",
      "entity2": "Insomnia",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia."
    },
    {
      "entity1": "Daridorexant",
      "entity2": "Insomnia",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia."
    },
    {
      "entity1": "Orexin",
      "entity2": "HCRTR1",
      "relationship": "binds_to",
      "confidence": 0.9,
      "pmid": "34052813",
      "evidence_sentence_indices": [
        1
      ],
      "evidence_text": "The hypocretins/orexins are two excitatory neuropeptides, alternately called HCRT1 or orexin-A and HCRT2 or orexin-B, that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R."
    },
    {
      "entity1": "Orexin",
      "entity2": "HCRTR2",
      "relationship": "binds_to",
      "confidence": 0.9,
      "pmid": "34052813",
      "evidence_sentence_indices": [
        1
      ],
      "evidence_text": "The hypocretins/orexins are two excitatory neuropeptides, alternately called HCRT1 or orexin-A and HCRT2 or orexin-B, that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R."
    },
    {
      "entity1": "Orexin",
      "entity2": "Narcolepsy",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "34052813",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Shortly after the discovery of this system, degeneration of hypocretin/orexin-producing neurons was implicated in the etiology of the sleep disorder narcolepsy."
    },
    {
      "entity1": "OX2R",
      "entity2": "Sleep Disorders",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "34052813",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "While HCRTR1/OX1R is associated with regulation of motivation, reward, and autonomic functions, HCRTR2/OX2R is strongly linked to sleep-wake control."
    },
    {
      "entity1": "Orexin",
      "entity2": "Sleep Disorders",
      "relationship": "regulates",
      "confidence": 0.9,
      "pmid": "34052810",
      "evidence_sentence_indices": [
        1
      ],
      "evidence_text": "Orexins regulate a wide variety of biological functions, most notably the sleep-wake cycle, reward and stress processing, alertness, vigilance, and cognitive functioning."
    },
    {
      "entity1": "Orexin",
      "entity2": "Narcolepsy",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "34052810",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
    },
    {
      "entity1": "Orexin",
      "entity2": "Anorexia nervosa",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "34052810",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
    },
    {
      "entity1": "Orexin",
      "entity2": "Cognitive decline",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "34052810",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
    },
    {
      "entity1": "Orexin",
      "entity2": "Neurodegenerative disease",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "34052810",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
    },
    {
      "entity1": "Sleep Disorders",
      "entity2": "Alzheimer's disease",
      "relationship": "cooccurs_with",
      "confidence": 0.9,
      "pmid": "37708433",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "Furthermore, evidence supports a bidirectional relationship between disrupted sleep and Alzheimer's disease (AD) or related dementias."
    },
    {
      "entity1": "Orexin",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "37708433",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "Dysregulation of the orexin system occurs in aging and AD, positioning ORAs as advantageous for these populations."
    },
    {
      "entity1": "Suvorexant",
      "entity2": "Dementia",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "37708433",
      "evidence_sentence_indices": [
        6
      ],
      "evidence_text": "Indeed, several clinical studies indicate that ORAs are efficacious hypnotics in older persons and dementia patients and, as in adults, are generally well tolerated."
    },
    {
      "entity1": "Suvorexant",
      "entity2": "Sleep Disorders",
      "relationship": "regulates",
      "confidence": 0.8,
      "pmid": "37708433",
      "evidence_sentence_indices": [
        7
      ],
      "evidence_text": "ORAs are likely to be more effective when administered early in sleep/wake dysregulation to reestablish good sleep/wake-related behaviors and reduce the accumulation of dementia-associated proteinopathic substrates."
    },
    {
      "entity1": "Orexin",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Given the high prevalence of sleep disturbances in Alzheimer's disease (AD) and their reported involvement in AD pathophysiology, the orexin system is hypothesized to contribute to the disease pathogenesis."
    },
    {
      "entity1": "Orexin",
      "entity2": "Amyloid-beta",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "Specifically, recent evidence suggests that orexin's influence may extend beyond sleep regulation, potentially affecting amyloid-\u03b2 and tau pathologies."
    },
    {
      "entity1": "Orexin",
      "entity2": "Tau",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "Specifically, recent evidence suggests that orexin's influence may extend beyond sleep regulation, potentially affecting amyloid-\u03b2 and tau pathologies."
    },
    {
      "entity1": "Suvorexant",
      "entity2": "Chronic insomnia disorder",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "Dual orexin receptor antagonists (DORAs), namely suvorexant, lemborexant, and daridorexant, demonstrated efficacy in treating chronic insomnia disorder across diverse clinical populations."
    },
    {
      "entity1": "Suvorexant",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        5,
        7
      ],
      "evidence_text": "Considering their stabilizing effects on sleep parameters and emerging evidence of a possible neuroprotective role, these agents represent a promising strategy for AD management. Overall, clinical studies support the use of DORAs to enhance sleep quality in patients with AD with comorbid sleep and circadian sleep-wake rhythm disorders."
    },
    {
      "entity1": "Lemborexant",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "Considering their stabilizing effects on sleep parameters and emerging evidence of a possible neuroprotective role, these agents represent a promising strategy for AD management."
    },
    {
      "entity1": "Daridorexant",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "Considering their stabilizing effects on sleep parameters and emerging evidence of a possible neuroprotective role, these agents represent a promising strategy for AD management."
    },
    {
      "entity1": "Orexin",
      "entity2": "OX1R",
      "relationship": "binds_to",
      "confidence": 0.9,
      "pmid": "31782044",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Orexins bind and activate their associated G protein-coupled orexin type 1 receptors (OX1Rs) and OX2Rs and act on numerous physiological processes, such as sleep-wake regulation, feeding, reward, emotion, and motivation."
    },
    {
      "entity1": "Orexin",
      "entity2": "OX2R",
      "relationship": "binds_to",
      "confidence": 0.9,
      "pmid": "31782044",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Orexins bind and activate their associated G protein-coupled orexin type 1 receptors (OX1Rs) and OX2Rs and act on numerous physiological processes, such as sleep-wake regulation, feeding, reward, emotion, and motivation."
    },
    {
      "entity1": "Orexin",
      "entity2": "Depression",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "31782044",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "In the present review, we discuss recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction."
    },
    {
      "entity1": "Orexin",
      "entity2": "Anxiety",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "31782044",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "In the present review, we discuss recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction."
    },
    {
      "entity1": "Orexin",
      "entity2": "Drug addiction",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "31782044",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "In the present review, we discuss recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "NF-kappaB",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "ERK",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "p38",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "IL-1beta",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "TNF-alpha",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "IL-6",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "iNOS",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "GFAP",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "Bcl-2",
      "relationship": "activates",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "Bax",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "Cytochrome C",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "caspase-9",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "caspase-3",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
    },
    {
      "entity1": "TAK-861",
      "entity2": "OX2R",
      "relationship": "activates",
      "confidence": 0.95,
      "pmid": "39242684",
      "evidence_sentence_indices": [
        6
      ],
      "evidence_text": "Here, we show that a novel OX2R-selective agonist, TAK-861 [N-{(2S,3R)-4,4-Difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3',5'-trifluoro[1,1'-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide], activates OX2R with a half-maximal effective concentration of 2.5\u00a0nM and promotes wakefulness at 1\u00a0mg/kg in mice and monkeys, suggesting ~\u2009tenfold higher potency and lower effective dosage than TAK-994."
    },
    {
      "entity1": "TAK-861",
      "entity2": "cataplexy",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "39242684",
      "evidence_sentence_indices": [
        7
      ],
      "evidence_text": "Similar to TAK-994, TAK-861 substantially ameliorates wakefulness fragmentation and cataplexy-like episodes in orexin/ataxin-3 and orexin-tTA;TetO DTA mice (NT1 mouse models)."
    },
    {
      "entity1": "TAK-994",
      "entity2": "OX2R",
      "relationship": "activates",
      "confidence": 0.85,
      "pmid": "37494485",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "METHODS: We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1."
    },
    {
      "entity1": "TAK-994",
      "entity2": "cataplexy",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "37494485",
      "evidence_sentence_indices": [
        13
      ],
      "evidence_text": "Weekly incidences of cataplexy at week 8 were 0.27 in the 30-mg group, 1.14 in the 90-mg group, 0.88 in the 180-mg group, and 5.83 in the placebo group (rate ratio vs."
    },
    {
      "entity1": "TAK-994",
      "entity2": "sleepiness",
      "relationship": "inhibits",
      "confidence": 0.85,
      "pmid": "37494485",
      "evidence_sentence_indices": [
        11,
        12
      ],
      "evidence_text": "Least-squares mean changes to week 8 in the ESS score were -12.2 in the 30-mg group, -13.5 in the 90-mg group, -15.1 in the 180-mg group, and -2.1 in the placebo group (difference vs. placebo, -10.1 in the 30-mg group, -11.4 in the 90-mg group, and -13.0 in the 180-mg group)."
    },
    {
      "entity1": "TAK-994",
      "entity2": "hepatotoxic effects",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "37494485",
      "evidence_sentence_indices": [
        15,
        16
      ],
      "evidence_text": "A total of 44 of 56 patients (79%) receiving TAK-994 had adverse events, most commonly urinary urgency or frequency. Clinically important elevations in liver-enzyme levels occurred in 5 patients, and drug-induced liver injury meeting Hy's law criteria occurred in 3 patients."
    },
    {
      "entity1": "HCRTR1",
      "entity2": "lactate",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "39119889",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "Excessive hypocretin-1 conducted with hypocretin receptor 1 (HCRTR1) reduced lactate production and brain-derived neurotrophic factor (BDNF) expression by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), thus impairing adult hippocampal neuroplasticity, and cognitive impairment in CUMS model."
    },
    {
      "entity1": "HCRTR1",
      "entity2": "BDNF",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "39119889",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "Excessive hypocretin-1 conducted with hypocretin receptor 1 (HCRTR1) reduced lactate production and brain-derived neurotrophic factor (BDNF) expression by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), thus impairing adult hippocampal neuroplasticity, and cognitive impairment in CUMS model."
    },
    {
      "entity1": "hypocretin-1",
      "entity2": "lactate",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "39119889",
      "evidence_sentence_indices": [
        4,
        6
      ],
      "evidence_text": "Excessive hypocretin-1 conducted with hypocretin receptor 1 (HCRTR1) reduced lactate production and brain-derived neurotrophic factor (BDNF) expression by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), thus impairing adult hippocampal neuroplasticity, and cognitive impairment in CUMS model. The direct effect of hypocretin-1 on hippocampal lactate production and cognitive behavior is further confirmed by intraventricular injection of hypocretin-1 and microPET-CT in rats."
    },
    {
      "entity1": "MSZRD",
      "entity2": "Orexin-A",
      "relationship": "regulates",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Our previous study showed that MSZRD can improve the gastrointestinal discomfort related insomnia by regulating Orexin-A."
    },
    {
      "entity1": "MSZRD",
      "entity2": "5-HT",
      "relationship": "regulates",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "5HT1A receptor",
      "relationship": "regulates",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "DA",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "norepinephrine",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "GABA",
      "relationship": "regulates",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        13
      ],
      "evidence_text": "Importantly, serum GABA concentration was increased by treatment with MSZRD (P\u00a0<\u00a00.05), as reflected by a decreased Glu/GABA ratio (P\u00a0<\u00a00.05)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "Glu",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        13
      ],
      "evidence_text": "Importantly, serum GABA concentration was increased by treatment with MSZRD (P\u00a0<\u00a00.05), as reflected by a decreased Glu/GABA ratio (P\u00a0<\u00a00.05)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "CORT",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        14
      ],
      "evidence_text": "Moreover, MSZRD decreased the levels of CORT, ACTH, and CRH related hormones in HPA axis (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "ACTH",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        14
      ],
      "evidence_text": "Moreover, MSZRD decreased the levels of CORT, ACTH, and CRH related hormones in HPA axis (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "CRH",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        14
      ],
      "evidence_text": "Moreover, MSZRD decreased the levels of CORT, ACTH, and CRH related hormones in HPA axis (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "Orexin-A",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        15
      ],
      "evidence_text": "At the same time, MSZRD significantly downregulated the serum Orexin-A content in insomnia mice (P\u00a0<\u00a00.05), as well as hypothalamic OX2R expression (P\u00a0<\u00a00.05)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        15
      ],
      "evidence_text": "At the same time, MSZRD significantly downregulated the serum Orexin-A content in insomnia mice (P\u00a0<\u00a00.05), as well as hypothalamic OX2R expression (P\u00a0<\u00a00.05)."
    },
    {
      "entity1": "sleep disorders",
      "entity2": "epilepsy",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "It is documented that sleep disorders are associated with epilepsy."
    },
    {
      "entity1": "sleep disorders",
      "entity2": "epileptic seizures",
      "relationship": "regulates",
      "confidence": 0.8,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "The origin, suppression, and spread of seizures are affected by sleep."
    },
    {
      "entity1": "Orexin",
      "entity2": "sleep disorders",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        7
      ],
      "evidence_text": "Meanwhile, orexin, a wake-promoting neuropeptide, provides a bidirectional effect on both sleep and epilepsy."
    },
    {
      "entity1": "Orexin",
      "entity2": "epilepsy",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        7
      ],
      "evidence_text": "Meanwhile, orexin, a wake-promoting neuropeptide, provides a bidirectional effect on both sleep and epilepsy."
    },
    {
      "entity1": "OX1R",
      "entity2": "Orexin",
      "relationship": "binds_to",
      "confidence": 0.95,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        8
      ],
      "evidence_text": "Orexin and its cognate receptors, orexin receptor type 1 (OX1R) and type 2 (OX2R), orchestrate their effects by activating various downstream signaling pathways."
    },
    {
      "entity1": "OX2R",
      "entity2": "Orexin",
      "relationship": "binds_to",
      "confidence": 0.95,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        8
      ],
      "evidence_text": "Orexin and its cognate receptors, orexin receptor type 1 (OX1R) and type 2 (OX2R), orchestrate their effects by activating various downstream signaling pathways."
    },
    {
      "entity1": "Orexin",
      "entity2": "psychiatric disorders",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        9
      ],
      "evidence_text": "Although orexin was considered a therapeutic target in insomnia shortly after its discovery, its potential usefulness for psychiatric disorders and epileptic seizures has been suggested in the pre-clinical studies."
    },
    {
      "entity1": "Orexin",
      "entity2": "epileptic seizures",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        9
      ],
      "evidence_text": "Although orexin was considered a therapeutic target in insomnia shortly after its discovery, its potential usefulness for psychiatric disorders and epileptic seizures has been suggested in the pre-clinical studies."
    }
  ],
  "valid_relationships": [
    {
      "entity1": "Almorexant",
      "entity2": "Orexin",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "Almorexant is now mainly used as a commercial specific inhibitor of the orexin system in animal studies due to safety issues."
    },
    {
      "entity1": "Filorexant",
      "entity2": "Insomnia",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "Although filorexant has also shown a certain sleep-promoting effect, there are few clinical or experimental studies on sleep-related aspects of filorexant in recent years."
    },
    {
      "entity1": "Seltorexant",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        6
      ],
      "evidence_text": "As for selective ORAs, orexin receptor 2 antagonist seltorexant still has not yet reached phase 3."
    },
    {
      "entity1": "Suvorexant",
      "entity2": "Insomnia",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia."
    },
    {
      "entity1": "Lemborexant",
      "entity2": "Insomnia",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia."
    },
    {
      "entity1": "Daridorexant",
      "entity2": "Insomnia",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "35972717",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia."
    },
    {
      "entity1": "Orexin",
      "entity2": "HCRTR1",
      "relationship": "binds_to",
      "confidence": 0.9,
      "pmid": "34052813",
      "evidence_sentence_indices": [
        1
      ],
      "evidence_text": "The hypocretins/orexins are two excitatory neuropeptides, alternately called HCRT1 or orexin-A and HCRT2 or orexin-B, that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R."
    },
    {
      "entity1": "Orexin",
      "entity2": "HCRTR2",
      "relationship": "binds_to",
      "confidence": 0.9,
      "pmid": "34052813",
      "evidence_sentence_indices": [
        1
      ],
      "evidence_text": "The hypocretins/orexins are two excitatory neuropeptides, alternately called HCRT1 or orexin-A and HCRT2 or orexin-B, that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R."
    },
    {
      "entity1": "Orexin",
      "entity2": "Narcolepsy",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "34052813",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Shortly after the discovery of this system, degeneration of hypocretin/orexin-producing neurons was implicated in the etiology of the sleep disorder narcolepsy."
    },
    {
      "entity1": "OX2R",
      "entity2": "Sleep Disorders",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "34052813",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "While HCRTR1/OX1R is associated with regulation of motivation, reward, and autonomic functions, HCRTR2/OX2R is strongly linked to sleep-wake control."
    },
    {
      "entity1": "Orexin",
      "entity2": "Sleep Disorders",
      "relationship": "regulates",
      "confidence": 0.9,
      "pmid": "34052810",
      "evidence_sentence_indices": [
        1
      ],
      "evidence_text": "Orexins regulate a wide variety of biological functions, most notably the sleep-wake cycle, reward and stress processing, alertness, vigilance, and cognitive functioning."
    },
    {
      "entity1": "Orexin",
      "entity2": "Narcolepsy",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "34052810",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
    },
    {
      "entity1": "Orexin",
      "entity2": "Anorexia nervosa",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "34052810",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
    },
    {
      "entity1": "Orexin",
      "entity2": "Cognitive decline",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "34052810",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
    },
    {
      "entity1": "Orexin",
      "entity2": "Neurodegenerative disease",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "34052810",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
    },
    {
      "entity1": "Sleep Disorders",
      "entity2": "Alzheimer's disease",
      "relationship": "cooccurs_with",
      "confidence": 0.9,
      "pmid": "37708433",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "Furthermore, evidence supports a bidirectional relationship between disrupted sleep and Alzheimer's disease (AD) or related dementias."
    },
    {
      "entity1": "Orexin",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "37708433",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "Dysregulation of the orexin system occurs in aging and AD, positioning ORAs as advantageous for these populations."
    },
    {
      "entity1": "Suvorexant",
      "entity2": "Dementia",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "37708433",
      "evidence_sentence_indices": [
        6
      ],
      "evidence_text": "Indeed, several clinical studies indicate that ORAs are efficacious hypnotics in older persons and dementia patients and, as in adults, are generally well tolerated."
    },
    {
      "entity1": "Suvorexant",
      "entity2": "Sleep Disorders",
      "relationship": "regulates",
      "confidence": 0.8,
      "pmid": "37708433",
      "evidence_sentence_indices": [
        7
      ],
      "evidence_text": "ORAs are likely to be more effective when administered early in sleep/wake dysregulation to reestablish good sleep/wake-related behaviors and reduce the accumulation of dementia-associated proteinopathic substrates."
    },
    {
      "entity1": "Orexin",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Given the high prevalence of sleep disturbances in Alzheimer's disease (AD) and their reported involvement in AD pathophysiology, the orexin system is hypothesized to contribute to the disease pathogenesis."
    },
    {
      "entity1": "Orexin",
      "entity2": "Amyloid-beta",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "Specifically, recent evidence suggests that orexin's influence may extend beyond sleep regulation, potentially affecting amyloid-\u03b2 and tau pathologies."
    },
    {
      "entity1": "Orexin",
      "entity2": "Tau",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        3
      ],
      "evidence_text": "Specifically, recent evidence suggests that orexin's influence may extend beyond sleep regulation, potentially affecting amyloid-\u03b2 and tau pathologies."
    },
    {
      "entity1": "Suvorexant",
      "entity2": "Chronic insomnia disorder",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "Dual orexin receptor antagonists (DORAs), namely suvorexant, lemborexant, and daridorexant, demonstrated efficacy in treating chronic insomnia disorder across diverse clinical populations."
    },
    {
      "entity1": "Suvorexant",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        5,
        7
      ],
      "evidence_text": "Considering their stabilizing effects on sleep parameters and emerging evidence of a possible neuroprotective role, these agents represent a promising strategy for AD management. Overall, clinical studies support the use of DORAs to enhance sleep quality in patients with AD with comorbid sleep and circadian sleep-wake rhythm disorders."
    },
    {
      "entity1": "Lemborexant",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "Considering their stabilizing effects on sleep parameters and emerging evidence of a possible neuroprotective role, these agents represent a promising strategy for AD management."
    },
    {
      "entity1": "Daridorexant",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "confidence": 0.85,
      "pmid": "39365407",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "Considering their stabilizing effects on sleep parameters and emerging evidence of a possible neuroprotective role, these agents represent a promising strategy for AD management."
    },
    {
      "entity1": "Orexin",
      "entity2": "OX1R",
      "relationship": "binds_to",
      "confidence": 0.9,
      "pmid": "31782044",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Orexins bind and activate their associated G protein-coupled orexin type 1 receptors (OX1Rs) and OX2Rs and act on numerous physiological processes, such as sleep-wake regulation, feeding, reward, emotion, and motivation."
    },
    {
      "entity1": "Orexin",
      "entity2": "OX2R",
      "relationship": "binds_to",
      "confidence": 0.9,
      "pmid": "31782044",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Orexins bind and activate their associated G protein-coupled orexin type 1 receptors (OX1Rs) and OX2Rs and act on numerous physiological processes, such as sleep-wake regulation, feeding, reward, emotion, and motivation."
    },
    {
      "entity1": "Orexin",
      "entity2": "Depression",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "31782044",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "In the present review, we discuss recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction."
    },
    {
      "entity1": "Orexin",
      "entity2": "Anxiety",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "31782044",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "In the present review, we discuss recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction."
    },
    {
      "entity1": "Orexin",
      "entity2": "Drug addiction",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "31782044",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "In the present review, we discuss recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "NF-kappaB",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "ERK",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "p38",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "IL-1beta",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "TNF-alpha",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "IL-6",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "iNOS",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "GFAP",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        11
      ],
      "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "Bcl-2",
      "relationship": "activates",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "Bax",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "Cytochrome C",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "caspase-9",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
    },
    {
      "entity1": "Orexin-A",
      "entity2": "caspase-3",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "34358627",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
    },
    {
      "entity1": "TAK-861",
      "entity2": "OX2R",
      "relationship": "activates",
      "confidence": 0.95,
      "pmid": "39242684",
      "evidence_sentence_indices": [
        6
      ],
      "evidence_text": "Here, we show that a novel OX2R-selective agonist, TAK-861 [N-{(2S,3R)-4,4-Difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3',5'-trifluoro[1,1'-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide], activates OX2R with a half-maximal effective concentration of 2.5\u00a0nM and promotes wakefulness at 1\u00a0mg/kg in mice and monkeys, suggesting ~\u2009tenfold higher potency and lower effective dosage than TAK-994."
    },
    {
      "entity1": "TAK-861",
      "entity2": "cataplexy",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "39242684",
      "evidence_sentence_indices": [
        7
      ],
      "evidence_text": "Similar to TAK-994, TAK-861 substantially ameliorates wakefulness fragmentation and cataplexy-like episodes in orexin/ataxin-3 and orexin-tTA;TetO DTA mice (NT1 mouse models)."
    },
    {
      "entity1": "TAK-994",
      "entity2": "OX2R",
      "relationship": "activates",
      "confidence": 0.85,
      "pmid": "37494485",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "METHODS: We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1."
    },
    {
      "entity1": "TAK-994",
      "entity2": "cataplexy",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "37494485",
      "evidence_sentence_indices": [
        13
      ],
      "evidence_text": "Weekly incidences of cataplexy at week 8 were 0.27 in the 30-mg group, 1.14 in the 90-mg group, 0.88 in the 180-mg group, and 5.83 in the placebo group (rate ratio vs."
    },
    {
      "entity1": "TAK-994",
      "entity2": "sleepiness",
      "relationship": "inhibits",
      "confidence": 0.85,
      "pmid": "37494485",
      "evidence_sentence_indices": [
        11,
        12
      ],
      "evidence_text": "Least-squares mean changes to week 8 in the ESS score were -12.2 in the 30-mg group, -13.5 in the 90-mg group, -15.1 in the 180-mg group, and -2.1 in the placebo group (difference vs. placebo, -10.1 in the 30-mg group, -11.4 in the 90-mg group, and -13.0 in the 180-mg group)."
    },
    {
      "entity1": "TAK-994",
      "entity2": "hepatotoxic effects",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "37494485",
      "evidence_sentence_indices": [
        15,
        16
      ],
      "evidence_text": "A total of 44 of 56 patients (79%) receiving TAK-994 had adverse events, most commonly urinary urgency or frequency. Clinically important elevations in liver-enzyme levels occurred in 5 patients, and drug-induced liver injury meeting Hy's law criteria occurred in 3 patients."
    },
    {
      "entity1": "HCRTR1",
      "entity2": "lactate",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "39119889",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "Excessive hypocretin-1 conducted with hypocretin receptor 1 (HCRTR1) reduced lactate production and brain-derived neurotrophic factor (BDNF) expression by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), thus impairing adult hippocampal neuroplasticity, and cognitive impairment in CUMS model."
    },
    {
      "entity1": "HCRTR1",
      "entity2": "BDNF",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "39119889",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "Excessive hypocretin-1 conducted with hypocretin receptor 1 (HCRTR1) reduced lactate production and brain-derived neurotrophic factor (BDNF) expression by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), thus impairing adult hippocampal neuroplasticity, and cognitive impairment in CUMS model."
    },
    {
      "entity1": "hypocretin-1",
      "entity2": "lactate",
      "relationship": "inhibits",
      "confidence": 0.9,
      "pmid": "39119889",
      "evidence_sentence_indices": [
        4,
        6
      ],
      "evidence_text": "Excessive hypocretin-1 conducted with hypocretin receptor 1 (HCRTR1) reduced lactate production and brain-derived neurotrophic factor (BDNF) expression by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), thus impairing adult hippocampal neuroplasticity, and cognitive impairment in CUMS model. The direct effect of hypocretin-1 on hippocampal lactate production and cognitive behavior is further confirmed by intraventricular injection of hypocretin-1 and microPET-CT in rats."
    },
    {
      "entity1": "MSZRD",
      "entity2": "Orexin-A",
      "relationship": "regulates",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        2
      ],
      "evidence_text": "Our previous study showed that MSZRD can improve the gastrointestinal discomfort related insomnia by regulating Orexin-A."
    },
    {
      "entity1": "MSZRD",
      "entity2": "5-HT",
      "relationship": "regulates",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "5HT1A receptor",
      "relationship": "regulates",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "DA",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "norepinephrine",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        12
      ],
      "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "GABA",
      "relationship": "regulates",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        13
      ],
      "evidence_text": "Importantly, serum GABA concentration was increased by treatment with MSZRD (P\u00a0<\u00a00.05), as reflected by a decreased Glu/GABA ratio (P\u00a0<\u00a00.05)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "Glu",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        13
      ],
      "evidence_text": "Importantly, serum GABA concentration was increased by treatment with MSZRD (P\u00a0<\u00a00.05), as reflected by a decreased Glu/GABA ratio (P\u00a0<\u00a00.05)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "CORT",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        14
      ],
      "evidence_text": "Moreover, MSZRD decreased the levels of CORT, ACTH, and CRH related hormones in HPA axis (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "ACTH",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        14
      ],
      "evidence_text": "Moreover, MSZRD decreased the levels of CORT, ACTH, and CRH related hormones in HPA axis (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "CRH",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        14
      ],
      "evidence_text": "Moreover, MSZRD decreased the levels of CORT, ACTH, and CRH related hormones in HPA axis (P\u00a0<\u00a00.05, 0.01)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "Orexin-A",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        15
      ],
      "evidence_text": "At the same time, MSZRD significantly downregulated the serum Orexin-A content in insomnia mice (P\u00a0<\u00a00.05), as well as hypothalamic OX2R expression (P\u00a0<\u00a00.05)."
    },
    {
      "entity1": "MSZRD",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "confidence": 0.95,
      "pmid": "34509822",
      "evidence_sentence_indices": [
        15
      ],
      "evidence_text": "At the same time, MSZRD significantly downregulated the serum Orexin-A content in insomnia mice (P\u00a0<\u00a00.05), as well as hypothalamic OX2R expression (P\u00a0<\u00a00.05)."
    },
    {
      "entity1": "sleep disorders",
      "entity2": "epilepsy",
      "relationship": "associated_with",
      "confidence": 0.9,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        4
      ],
      "evidence_text": "It is documented that sleep disorders are associated with epilepsy."
    },
    {
      "entity1": "sleep disorders",
      "entity2": "epileptic seizures",
      "relationship": "regulates",
      "confidence": 0.8,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        5
      ],
      "evidence_text": "The origin, suppression, and spread of seizures are affected by sleep."
    },
    {
      "entity1": "Orexin",
      "entity2": "sleep disorders",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        7
      ],
      "evidence_text": "Meanwhile, orexin, a wake-promoting neuropeptide, provides a bidirectional effect on both sleep and epilepsy."
    },
    {
      "entity1": "Orexin",
      "entity2": "epilepsy",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        7
      ],
      "evidence_text": "Meanwhile, orexin, a wake-promoting neuropeptide, provides a bidirectional effect on both sleep and epilepsy."
    },
    {
      "entity1": "OX1R",
      "entity2": "Orexin",
      "relationship": "binds_to",
      "confidence": 0.95,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        8
      ],
      "evidence_text": "Orexin and its cognate receptors, orexin receptor type 1 (OX1R) and type 2 (OX2R), orchestrate their effects by activating various downstream signaling pathways."
    },
    {
      "entity1": "OX2R",
      "entity2": "Orexin",
      "relationship": "binds_to",
      "confidence": 0.95,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        8
      ],
      "evidence_text": "Orexin and its cognate receptors, orexin receptor type 1 (OX1R) and type 2 (OX2R), orchestrate their effects by activating various downstream signaling pathways."
    },
    {
      "entity1": "Orexin",
      "entity2": "psychiatric disorders",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        9
      ],
      "evidence_text": "Although orexin was considered a therapeutic target in insomnia shortly after its discovery, its potential usefulness for psychiatric disorders and epileptic seizures has been suggested in the pre-clinical studies."
    },
    {
      "entity1": "Orexin",
      "entity2": "epileptic seizures",
      "relationship": "associated_with",
      "confidence": 0.8,
      "pmid": "37003137",
      "evidence_sentence_indices": [
        9
      ],
      "evidence_text": "Although orexin was considered a therapeutic target in insomnia shortly after its discovery, its potential usefulness for psychiatric disorders and epileptic seizures has been suggested in the pre-clinical studies."
    }
  ],
  "validation_results": [
    {
      "relationship": {
        "entity1": "Almorexant",
        "entity2": "Orexin",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "35972717",
        "evidence_sentence_indices": [
          4
        ],
        "evidence_text": "Almorexant is now mainly used as a commercial specific inhibitor of the orexin system in animal studies due to safety issues."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Filorexant",
        "entity2": "Insomnia",
        "relationship": "associated_with",
        "confidence": 0.8,
        "pmid": "35972717",
        "evidence_sentence_indices": [
          5
        ],
        "evidence_text": "Although filorexant has also shown a certain sleep-promoting effect, there are few clinical or experimental studies on sleep-related aspects of filorexant in recent years."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Seltorexant",
        "entity2": "OX2R",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "35972717",
        "evidence_sentence_indices": [
          6
        ],
        "evidence_text": "As for selective ORAs, orexin receptor 2 antagonist seltorexant still has not yet reached phase 3."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Suvorexant",
        "entity2": "Insomnia",
        "relationship": "associated_with",
        "confidence": 0.8,
        "pmid": "35972717",
        "evidence_sentence_indices": [
          3
        ],
        "evidence_text": "RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Lemborexant",
        "entity2": "Insomnia",
        "relationship": "associated_with",
        "confidence": 0.8,
        "pmid": "35972717",
        "evidence_sentence_indices": [
          3
        ],
        "evidence_text": "RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Daridorexant",
        "entity2": "Insomnia",
        "relationship": "associated_with",
        "confidence": 0.8,
        "pmid": "35972717",
        "evidence_sentence_indices": [
          3
        ],
        "evidence_text": "RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "HCRTR1",
        "relationship": "binds_to",
        "confidence": 0.9,
        "pmid": "34052813",
        "evidence_sentence_indices": [
          1
        ],
        "evidence_text": "The hypocretins/orexins are two excitatory neuropeptides, alternately called HCRT1 or orexin-A and HCRT2 or orexin-B, that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "HCRTR2",
        "relationship": "binds_to",
        "confidence": 0.9,
        "pmid": "34052813",
        "evidence_sentence_indices": [
          1
        ],
        "evidence_text": "The hypocretins/orexins are two excitatory neuropeptides, alternately called HCRT1 or orexin-A and HCRT2 or orexin-B, that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Narcolepsy",
        "relationship": "associated_with",
        "confidence": 0.9,
        "pmid": "34052813",
        "evidence_sentence_indices": [
          2
        ],
        "evidence_text": "Shortly after the discovery of this system, degeneration of hypocretin/orexin-producing neurons was implicated in the etiology of the sleep disorder narcolepsy."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "Sleep Disorders",
        "relationship": "associated_with",
        "confidence": 0.85,
        "pmid": "34052813",
        "evidence_sentence_indices": [
          5
        ],
        "evidence_text": "While HCRTR1/OX1R is associated with regulation of motivation, reward, and autonomic functions, HCRTR2/OX2R is strongly linked to sleep-wake control."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Sleep Disorders",
        "relationship": "regulates",
        "confidence": 0.9,
        "pmid": "34052810",
        "evidence_sentence_indices": [
          1
        ],
        "evidence_text": "Orexins regulate a wide variety of biological functions, most notably the sleep-wake cycle, reward and stress processing, alertness, vigilance, and cognitive functioning."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Narcolepsy",
        "relationship": "associated_with",
        "confidence": 0.9,
        "pmid": "34052810",
        "evidence_sentence_indices": [
          2
        ],
        "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Anorexia nervosa",
        "relationship": "associated_with",
        "confidence": 0.85,
        "pmid": "34052810",
        "evidence_sentence_indices": [
          2
        ],
        "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Cognitive decline",
        "relationship": "associated_with",
        "confidence": 0.85,
        "pmid": "34052810",
        "evidence_sentence_indices": [
          2
        ],
        "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Neurodegenerative disease",
        "relationship": "associated_with",
        "confidence": 0.85,
        "pmid": "34052810",
        "evidence_sentence_indices": [
          2
        ],
        "evidence_text": "Alterations of central and peripheral orexin levels are linked to conditions such as narcolepsy, anorexia nervosa, age-related cognitive decline, and neurodegenerative disease."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Sleep Disorders",
        "entity2": "Alzheimer's disease",
        "relationship": "cooccurs_with",
        "confidence": 0.9,
        "pmid": "37708433",
        "evidence_sentence_indices": [
          3
        ],
        "evidence_text": "Furthermore, evidence supports a bidirectional relationship between disrupted sleep and Alzheimer's disease (AD) or related dementias."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Alzheimer's disease",
        "relationship": "associated_with",
        "confidence": 0.9,
        "pmid": "37708433",
        "evidence_sentence_indices": [
          5
        ],
        "evidence_text": "Dysregulation of the orexin system occurs in aging and AD, positioning ORAs as advantageous for these populations."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Suvorexant",
        "entity2": "Dementia",
        "relationship": "associated_with",
        "confidence": 0.85,
        "pmid": "37708433",
        "evidence_sentence_indices": [
          6
        ],
        "evidence_text": "Indeed, several clinical studies indicate that ORAs are efficacious hypnotics in older persons and dementia patients and, as in adults, are generally well tolerated."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Suvorexant",
        "entity2": "Sleep Disorders",
        "relationship": "regulates",
        "confidence": 0.8,
        "pmid": "37708433",
        "evidence_sentence_indices": [
          7
        ],
        "evidence_text": "ORAs are likely to be more effective when administered early in sleep/wake dysregulation to reestablish good sleep/wake-related behaviors and reduce the accumulation of dementia-associated proteinopathic substrates."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Alzheimer's disease",
        "relationship": "associated_with",
        "confidence": 0.9,
        "pmid": "39365407",
        "evidence_sentence_indices": [
          2
        ],
        "evidence_text": "Given the high prevalence of sleep disturbances in Alzheimer's disease (AD) and their reported involvement in AD pathophysiology, the orexin system is hypothesized to contribute to the disease pathogenesis."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Amyloid-beta",
        "relationship": "associated_with",
        "confidence": 0.85,
        "pmid": "39365407",
        "evidence_sentence_indices": [
          3
        ],
        "evidence_text": "Specifically, recent evidence suggests that orexin's influence may extend beyond sleep regulation, potentially affecting amyloid-\u03b2 and tau pathologies."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Tau",
        "relationship": "associated_with",
        "confidence": 0.85,
        "pmid": "39365407",
        "evidence_sentence_indices": [
          3
        ],
        "evidence_text": "Specifically, recent evidence suggests that orexin's influence may extend beyond sleep regulation, potentially affecting amyloid-\u03b2 and tau pathologies."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Suvorexant",
        "entity2": "Chronic insomnia disorder",
        "relationship": "associated_with",
        "confidence": 0.9,
        "pmid": "39365407",
        "evidence_sentence_indices": [
          4
        ],
        "evidence_text": "Dual orexin receptor antagonists (DORAs), namely suvorexant, lemborexant, and daridorexant, demonstrated efficacy in treating chronic insomnia disorder across diverse clinical populations."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Suvorexant",
        "entity2": "Alzheimer's disease",
        "relationship": "associated_with",
        "confidence": 0.85,
        "pmid": "39365407",
        "evidence_sentence_indices": [
          5,
          7
        ],
        "evidence_text": "Considering their stabilizing effects on sleep parameters and emerging evidence of a possible neuroprotective role, these agents represent a promising strategy for AD management. Overall, clinical studies support the use of DORAs to enhance sleep quality in patients with AD with comorbid sleep and circadian sleep-wake rhythm disorders."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Lemborexant",
        "entity2": "Alzheimer's disease",
        "relationship": "associated_with",
        "confidence": 0.85,
        "pmid": "39365407",
        "evidence_sentence_indices": [
          5
        ],
        "evidence_text": "Considering their stabilizing effects on sleep parameters and emerging evidence of a possible neuroprotective role, these agents represent a promising strategy for AD management."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Daridorexant",
        "entity2": "Alzheimer's disease",
        "relationship": "associated_with",
        "confidence": 0.85,
        "pmid": "39365407",
        "evidence_sentence_indices": [
          5
        ],
        "evidence_text": "Considering their stabilizing effects on sleep parameters and emerging evidence of a possible neuroprotective role, these agents represent a promising strategy for AD management."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "OX1R",
        "relationship": "binds_to",
        "confidence": 0.9,
        "pmid": "31782044",
        "evidence_sentence_indices": [
          2
        ],
        "evidence_text": "Orexins bind and activate their associated G protein-coupled orexin type 1 receptors (OX1Rs) and OX2Rs and act on numerous physiological processes, such as sleep-wake regulation, feeding, reward, emotion, and motivation."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "OX2R",
        "relationship": "binds_to",
        "confidence": 0.9,
        "pmid": "31782044",
        "evidence_sentence_indices": [
          2
        ],
        "evidence_text": "Orexins bind and activate their associated G protein-coupled orexin type 1 receptors (OX1Rs) and OX2Rs and act on numerous physiological processes, such as sleep-wake regulation, feeding, reward, emotion, and motivation."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Depression",
        "relationship": "associated_with",
        "confidence": 0.9,
        "pmid": "31782044",
        "evidence_sentence_indices": [
          4
        ],
        "evidence_text": "In the present review, we discuss recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Anxiety",
        "relationship": "associated_with",
        "confidence": 0.9,
        "pmid": "31782044",
        "evidence_sentence_indices": [
          4
        ],
        "evidence_text": "In the present review, we discuss recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "Drug addiction",
        "relationship": "associated_with",
        "confidence": 0.9,
        "pmid": "31782044",
        "evidence_sentence_indices": [
          4
        ],
        "evidence_text": "In the present review, we discuss recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "NF-kappaB",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          11
        ],
        "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "ERK",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          11
        ],
        "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "p38",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          11
        ],
        "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "IL-1beta",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          11
        ],
        "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "TNF-alpha",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          11
        ],
        "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "IL-6",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          11
        ],
        "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "iNOS",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          11
        ],
        "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "GFAP",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          11
        ],
        "evidence_text": "OXA decreased inflammatory mediators, inhibited astrocyte activation and nuclear translocation of NF-\u03baB and phosphorylation of NF-\u03baB, MAPK/ERK and MAPK/p38."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "Bcl-2",
        "relationship": "activates",
        "confidence": 0.9,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          12
        ],
        "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "Bax",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          12
        ],
        "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "Cytochrome C",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          12
        ],
        "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "caspase-9",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          12
        ],
        "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "caspase-3",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "34358627",
        "evidence_sentence_indices": [
          12
        ],
        "evidence_text": "Besides, OXA suppressed apoptosis via upregulating the ratio of Bcl-2/Bax and downregulating cytochrome C, cleaved-caspase-9 and cleaved caspase-3."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "TAK-861",
        "entity2": "OX2R",
        "relationship": "activates",
        "confidence": 0.95,
        "pmid": "39242684",
        "evidence_sentence_indices": [
          6
        ],
        "evidence_text": "Here, we show that a novel OX2R-selective agonist, TAK-861 [N-{(2S,3R)-4,4-Difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3',5'-trifluoro[1,1'-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide], activates OX2R with a half-maximal effective concentration of 2.5\u00a0nM and promotes wakefulness at 1\u00a0mg/kg in mice and monkeys, suggesting ~\u2009tenfold higher potency and lower effective dosage than TAK-994."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "TAK-861",
        "entity2": "cataplexy",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "39242684",
        "evidence_sentence_indices": [
          7
        ],
        "evidence_text": "Similar to TAK-994, TAK-861 substantially ameliorates wakefulness fragmentation and cataplexy-like episodes in orexin/ataxin-3 and orexin-tTA;TetO DTA mice (NT1 mouse models)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "TAK-994",
        "entity2": "OX2R",
        "relationship": "activates",
        "confidence": 0.85,
        "pmid": "37494485",
        "evidence_sentence_indices": [
          2
        ],
        "evidence_text": "METHODS: We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "TAK-994",
        "entity2": "cataplexy",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "37494485",
        "evidence_sentence_indices": [
          13
        ],
        "evidence_text": "Weekly incidences of cataplexy at week 8 were 0.27 in the 30-mg group, 1.14 in the 90-mg group, 0.88 in the 180-mg group, and 5.83 in the placebo group (rate ratio vs."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "TAK-994",
        "entity2": "sleepiness",
        "relationship": "inhibits",
        "confidence": 0.85,
        "pmid": "37494485",
        "evidence_sentence_indices": [
          11,
          12
        ],
        "evidence_text": "Least-squares mean changes to week 8 in the ESS score were -12.2 in the 30-mg group, -13.5 in the 90-mg group, -15.1 in the 180-mg group, and -2.1 in the placebo group (difference vs. placebo, -10.1 in the 30-mg group, -11.4 in the 90-mg group, and -13.0 in the 180-mg group)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "TAK-994",
        "entity2": "hepatotoxic effects",
        "relationship": "associated_with",
        "confidence": 0.8,
        "pmid": "37494485",
        "evidence_sentence_indices": [
          15,
          16
        ],
        "evidence_text": "A total of 44 of 56 patients (79%) receiving TAK-994 had adverse events, most commonly urinary urgency or frequency. Clinically important elevations in liver-enzyme levels occurred in 5 patients, and drug-induced liver injury meeting Hy's law criteria occurred in 3 patients."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "HCRTR1",
        "entity2": "lactate",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "39119889",
        "evidence_sentence_indices": [
          4
        ],
        "evidence_text": "Excessive hypocretin-1 conducted with hypocretin receptor 1 (HCRTR1) reduced lactate production and brain-derived neurotrophic factor (BDNF) expression by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), thus impairing adult hippocampal neuroplasticity, and cognitive impairment in CUMS model."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "HCRTR1",
        "entity2": "BDNF",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "39119889",
        "evidence_sentence_indices": [
          4
        ],
        "evidence_text": "Excessive hypocretin-1 conducted with hypocretin receptor 1 (HCRTR1) reduced lactate production and brain-derived neurotrophic factor (BDNF) expression by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), thus impairing adult hippocampal neuroplasticity, and cognitive impairment in CUMS model."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "hypocretin-1",
        "entity2": "lactate",
        "relationship": "inhibits",
        "confidence": 0.9,
        "pmid": "39119889",
        "evidence_sentence_indices": [
          4,
          6
        ],
        "evidence_text": "Excessive hypocretin-1 conducted with hypocretin receptor 1 (HCRTR1) reduced lactate production and brain-derived neurotrophic factor (BDNF) expression by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), thus impairing adult hippocampal neuroplasticity, and cognitive impairment in CUMS model. The direct effect of hypocretin-1 on hippocampal lactate production and cognitive behavior is further confirmed by intraventricular injection of hypocretin-1 and microPET-CT in rats."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "Orexin-A",
        "relationship": "regulates",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          2
        ],
        "evidence_text": "Our previous study showed that MSZRD can improve the gastrointestinal discomfort related insomnia by regulating Orexin-A."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "5-HT",
        "relationship": "regulates",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          12
        ],
        "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "5HT1A receptor",
        "relationship": "regulates",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          12
        ],
        "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "DA",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          12
        ],
        "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "norepinephrine",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          12
        ],
        "evidence_text": "Furthermore, MSZRD effectively increased the content of 5-HT and 5-HTR1A protein in the hypothalamus of insomnia mice (P\u00a0<\u00a00.05, 0.01), while downregulated the content of DA and NE (P\u00a0<\u00a00.05, 0.01)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "GABA",
        "relationship": "regulates",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          13
        ],
        "evidence_text": "Importantly, serum GABA concentration was increased by treatment with MSZRD (P\u00a0<\u00a00.05), as reflected by a decreased Glu/GABA ratio (P\u00a0<\u00a00.05)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "Glu",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          13
        ],
        "evidence_text": "Importantly, serum GABA concentration was increased by treatment with MSZRD (P\u00a0<\u00a00.05), as reflected by a decreased Glu/GABA ratio (P\u00a0<\u00a00.05)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "CORT",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          14
        ],
        "evidence_text": "Moreover, MSZRD decreased the levels of CORT, ACTH, and CRH related hormones in HPA axis (P\u00a0<\u00a00.05, 0.01)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "ACTH",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          14
        ],
        "evidence_text": "Moreover, MSZRD decreased the levels of CORT, ACTH, and CRH related hormones in HPA axis (P\u00a0<\u00a00.05, 0.01)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "CRH",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          14
        ],
        "evidence_text": "Moreover, MSZRD decreased the levels of CORT, ACTH, and CRH related hormones in HPA axis (P\u00a0<\u00a00.05, 0.01)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "Orexin-A",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          15
        ],
        "evidence_text": "At the same time, MSZRD significantly downregulated the serum Orexin-A content in insomnia mice (P\u00a0<\u00a00.05), as well as hypothalamic OX2R expression (P\u00a0<\u00a00.05)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "OX2R",
        "relationship": "inhibits",
        "confidence": 0.95,
        "pmid": "34509822",
        "evidence_sentence_indices": [
          15
        ],
        "evidence_text": "At the same time, MSZRD significantly downregulated the serum Orexin-A content in insomnia mice (P\u00a0<\u00a00.05), as well as hypothalamic OX2R expression (P\u00a0<\u00a00.05)."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "sleep disorders",
        "entity2": "epilepsy",
        "relationship": "associated_with",
        "confidence": 0.9,
        "pmid": "37003137",
        "evidence_sentence_indices": [
          4
        ],
        "evidence_text": "It is documented that sleep disorders are associated with epilepsy."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "sleep disorders",
        "entity2": "epileptic seizures",
        "relationship": "regulates",
        "confidence": 0.8,
        "pmid": "37003137",
        "evidence_sentence_indices": [
          5
        ],
        "evidence_text": "The origin, suppression, and spread of seizures are affected by sleep."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "sleep disorders",
        "relationship": "associated_with",
        "confidence": 0.8,
        "pmid": "37003137",
        "evidence_sentence_indices": [
          7
        ],
        "evidence_text": "Meanwhile, orexin, a wake-promoting neuropeptide, provides a bidirectional effect on both sleep and epilepsy."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "epilepsy",
        "relationship": "associated_with",
        "confidence": 0.8,
        "pmid": "37003137",
        "evidence_sentence_indices": [
          7
        ],
        "evidence_text": "Meanwhile, orexin, a wake-promoting neuropeptide, provides a bidirectional effect on both sleep and epilepsy."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX1R",
        "entity2": "Orexin",
        "relationship": "binds_to",
        "confidence": 0.95,
        "pmid": "37003137",
        "evidence_sentence_indices": [
          8
        ],
        "evidence_text": "Orexin and its cognate receptors, orexin receptor type 1 (OX1R) and type 2 (OX2R), orchestrate their effects by activating various downstream signaling pathways."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "Orexin",
        "relationship": "binds_to",
        "confidence": 0.95,
        "pmid": "37003137",
        "evidence_sentence_indices": [
          8
        ],
        "evidence_text": "Orexin and its cognate receptors, orexin receptor type 1 (OX1R) and type 2 (OX2R), orchestrate their effects by activating various downstream signaling pathways."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "psychiatric disorders",
        "relationship": "associated_with",
        "confidence": 0.8,
        "pmid": "37003137",
        "evidence_sentence_indices": [
          9
        ],
        "evidence_text": "Although orexin was considered a therapeutic target in insomnia shortly after its discovery, its potential usefulness for psychiatric disorders and epileptic seizures has been suggested in the pre-clinical studies."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "epileptic seizures",
        "relationship": "associated_with",
        "confidence": 0.8,
        "pmid": "37003137",
        "evidence_sentence_indices": [
          9
        ],
        "evidence_text": "Although orexin was considered a therapeutic target in insomnia shortly after its discovery, its potential usefulness for psychiatric disorders and epileptic seizures has been suggested in the pre-clinical studies."
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    }
  ],
  "statistics": {
    "total_abstracts": 15,
    "total_chunks": 3,
    "chunks_processed": 3,
    "total_relationships": 73,
    "valid_relationships": 73,
    "invalid_relationships": 0,
    "pmid_failures": 0,
    "evidence_failures": 0,
    "validation_rate": 1.0,
    "total_prompt_tokens": 7805,
    "total_completion_tokens": 13040,
    "total_latency_ms": 9916.238784790039,
    "wall_clock_ms": 4133.6798667907715,
    "throughput_tok_per_sec": 2102.107507936676
  },
  "errors": []
}